Lilly to seek FDA approval for potential Alzheimer’s drug

By
AP News
-
FILE- In this April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly’s new COVID-19 treatment helped the drugmaker’s fourth-quarter profit surge even though U.S. regulators approved its use late in the quarter. The antibody treatment bamlanivimab brought in $871 million in sales for Lilly after the Food and Drug Administration authorized emergency use in November 2020 for patients with mild-to-moderate COVID-19. . (AP Photo/Darron Cummings, File)

INDIANAPOLIS (AP) — Eli Lilly says it will submit its potential Alzheimer’s treatment to federal regulators later this year.

The announcement comes a few weeks after the Food and Drug Administration approved a treatment from rival Biogen despite warnings from the agency’s independent advisers that it hasn’t been shown to help slow the brain-destroying disease.

Lilly said Thursday that it will seek approval for its potential treatment, donanemab, based on data from a mid-stage clinical study of the drug involving 272 patients. Company shares rose around 7% in pre-market trading.

RELATED ARTICLESMORE FROM AUTHOR